½Å°úÇÐ/öÇÐ
Ãʽɸ®ÇÐ/ÀáÀç´É·Â
UFO/½Å¹°¸®ÇÐ
¿ÀÄÃƼÁò/¹Ì½ºÅ͸®

°úÇÐÀû, ºñ°úÇÐÀû ÀÇÇÐ
µ¿¼­¾ç ´ëüÀÇÇÐ

âÁ¶·Ð/°úÇÐÀû »ç½Ç¼º
âÁ¶·Ð/öÇаú Á¤Ä¡

½ºÄÎƽ½º/±âŸ ÁÖÁ¦
KOPSA ¹Ú¹°°ü

 

´ëÁ߸Åü ¸ð´ÏÅ͸µ
Áú¹®°ú ´ä

Åä·Ð¹æ¹ý
Åä·Ð»ç·Ê

¿¬±¸È¸¿ø °Ô½ÃÆÇ
¿¬±¸À§¿ø °Ô½ÃÆÇ

 

½ºÄÎƽ½º/±âŸ ÁÖÁ¦
   
  ´ëüÀÇÇÐÀ» º¸´Â ½Ã°¢(2) ¶óÀ̳ʽº Æú¸µ°ú ºñŸ¹ÎC ¾Ï ¿ä¹ý
  ±Û¾´ÀÌ : kopsa     ³¯Â¥ : 14-05-10 14:33     Á¶È¸ : 2878    
´ëüÀÇÇÐÀ» º¸´Â ½Ã°¢(2) ¶óÀ̳ʽº Æú¸µ°ú ºñŸ¹ÎC ¾Ï ¿ä¹ý

¿À·¡Àü ÇÑ°Ü·¹21(2001.02.28. Á¦348È£)¿¡ ¿¬ÀçÄ®·³À¸·Î Àû¾ú´ø ¡°¾ÏȯÀÚ¸¦ À§ÇÑ ºñŸ¹ÎC ¿ä¹ý¡±ÀÇ ¸µÅ©´Â ¾Æ·¡¿Í °°½À´Ï´Ù. Àüü ±ÛÀ» Àо½Ã±â ¹Ù¶ø´Ï´Ù. ¸¶Áö¸· ´ë¸ñÀÇ ¾ÕºÎºÐÀ»  ¿Å°Ü ÀûÀ¸¸é  ¾Æ·¡¿Í °°½À´Ï´Ù.     

(°­°ÇÀÏÀÇ °úÇÐÀбâ, ¾ÏȯÀÚ¸¦ À§ÇÑ ºñŸ¹ÎC ¿ä¹ý) 
http://h21.hani.co.kr/arti/culture/science/1820.html

¡°±× µÚ ºÐÀÚ±³Á¤ÀÇÇÐÀº ´ëüÀÇÇÐÀ¸·Î ¸í¸ÆÀ» À¯ÁöÇÑ Ã¤ Æú¸µÀÇ ºÒ¸í¿¹·Î ³²°Ô µÆ´Ù. ±×·¯´ø °ÍÀÌ 2001³â 2¿ù È£ÆÛ µîÀº <ij³ª´Ù ÀÇÇÐÇùȸÁö>¿¡ ¸ÞÀÌ¿äŬ¸®´ÐÀÇ ¹®Á¦¸¦ ºÐ¼®ÇÑ ³í¹®À» ¹ßÇ¥Çß´Ù. ÀϺΠ½ÃÇèÀÌ ´Ü±â Åõ¿©¿¡ ±×ÃÆÀ¸¸ç Ä«¸Þ·ÐÀÇ °á°ú¸¦ È®½ÇÈ÷ Çϱâ À§ÇÑ Á¤¸Æ Åõ¿©¸¦ ½ÃÇèÇÏÁö ¾ÊÀº ¹®Á¦ÀÇ ÁöÀûÀ̾ú´Ù. °í¿ë·® °æ±¸ Åõ¿©¿¡¼­ ºñŸ¹ÎC´Â Èí¼öÀ²ÀÌ ¶³¾îÁö°í ¼ÓÈ÷ ¹è¼³µÇ±â ¶§¹®¿¡ Á¤¸Æ Åõ¿©¿¡ ÀÇÇؼ­¸¸ ÀûÀýÇÑ Ä¡·á ³óµµ¿¡ À̸¥´Ù´Â ºÐ¼®À̾ú´Ù.¡±

1. ¾àÀÇ Ã¼³» µ¿Å¿¡ ´ëÇÑ ÀÌÇØ   

À§ÀÇ Àο뿡¼­ ¡°°í¿ë·® °æ±¸ Åõ¿©¿¡¼­ ºñŸ¹ÎC´Â Èí¼öÀ²ÀÌ ¶³¾îÁö°í ¼ÓÈ÷ ¹è¼³µÇ±â ¶§¹®¿¡ Á¤¸Æ Åõ¿©¿¡ ÀÇÇؼ­¸¸ ÀûÀýÇÑ Ä¡·á ³óµµ¿¡ À̸¥´Ù´Â ºÐ¼®À̾ú´Ù.¡±´Â ´ë¸ñÀÌ Áß¿äÇÕ´Ï´Ù. °£´ÜÈ÷ ¸»ÇØ ¾àÀº Åõ¿© ÈÄ¿¡ ±× È°¼º ¼ººÐÀÌ ÀÏÁ¤ ¾à ÀÛ¿ë ºÎÀ§¿¡ ºÐÆ÷µÇ¾î ÀÏÁ¤ ½Ã°£ Ä¡·á ³óµµ¸¦ À¯ÁöÇØ¾ß È¿°ú¸¦ ³ªÅ¸³À´Ï´Ù.

¾à °³¹ß¿¡¼­ ÀüÀÓ»ó µ¿¹° ½ÇÇè¿¡¼­ ±×¸®°í ÀÓ»ó 1»ó¿¡¼­ ¾àÀÇ Èí¼ö.ºÐÆ÷.´ë»ç.¹è¼³¿¡ °üÇÑ, ¾àÀÇ Ã¼³» µ¿Å¸¦ ¿¬±¸ÇÏ´Â ÀÌÀ¯°¡ ÀÌ°ÍÀÔ´Ï´Ù. ¶§¹®¿¡ Æú¸µÀÌ ÁÖÀåÇÏ´Â ºñŸ¹Î CÀÇ Ç×¾Ï È¿°ú¸¦ È®Á¤Çϱâ À§Çؼ­´Â °í¿ë·®À» Á¤¸Æ Åõ¿©ÇÏ¿© ½ÃÇèÇØ º¼ ÇÊ¿ä°¡ ÀÖ´Ù´Â ³í¸®´Â Áö±ØÈ÷ ÇÕ¸®ÀûÀÔ´Ï´Ù.     

2. ´ëüÀÇÇаú ¾à ÀÛ¿ë ¸ÞÄ¿´ÏÁò

À§¿¡ ÀÌ¾î ¾Æ·¡ ÀοëÇÑ ¸¶Áö¸· ´ë¸ñÀº ¡°´ëüÀÇÇÐÀ» º¸´Â ½Ã°¢¡±¿¡¼­ Áß¿äÇÑ ºÎºÐÀÔ´Ï´Ù. ¾àÀº ÀÓ»ó ½ÃÇè ÀÌÀü, ÀüÀÓ»ó ´Ü°è¿¡¼­ ±× ¾àÀÌ È¿°ú¸¦ ³ªÅ¸³¾ ÀÌ·ÐÀû °¡´É¼º, Áï ¾à ÀÛ¿ë ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ½ÇÇèÀ» ÇÕ´Ï´Ù. ÀÌ°ÍÀº ¶ÇÇÑ ¾à ¿¬±¸.°³¹ßÀÇ Ãâ¹ßÁ¡À̱⵵ ÇÕ´Ï´Ù. ´ëüÀÇÇа赵 Á¤ÅëÀÇÇа赵 ÀÓ»óÀû ÁÖÀå»Ó¸¸ ¾Æ´Ï¶ó ¾à ÀÛ¿ëÀÇ °¡´É¼ºÀ» ÇÔ²² ¸»ÇÒ ÇÊ¿ä°¡ ÀÖ½À´Ï´Ù.   

¡°À̵éÀº Æú¸µ°ú ÀÇÇаèÀÇ ³íÀï¿¡¼­ Æú¸µÀº °¡¼³Àû °¡´É¼ºÀ» ¿°µÎ¿¡ µÎ°íµµ À̸¦ ³íÀï¿¡ È°¿ëÇÏÁö ¾ÊÀº ¹Ý¸é ÀÇÇа迡¼­´Â ÀÓ»óÀû Áõ°Å Áß½ÉÀ¸·Î, ±×°Íµµ ¼­µÑ·¯ ºÎÁ¤Àû °á·ÐÀ» ³»·È´Ù°í ÁöÀûÇß´Ù. ¶ÇÇÑ ´ëüÀÇÇеµ ÀÌ·ÐÀû °¡´É¼º°ú Áõ°Å ¸ðµÎ¸¦ ¿°µÎ¿¡ µÎ¾î¾ß ÇÏÁö¸¸ Á¤ÅëÀÇÇа迡 ´ëüÀÇÇÐÀ» ½±°Ô ºÎÁ¤ÇÏ´Â Æí°ßÀÌ Á¸ÀçÇÑ´Ù°í ¾ð±ÞÇß´Ù.¡°

3. ºñŸ¹ÎCÀÇ Ç×¾Ï ¸ÞÄ¿´ÏÁò   

¹Ì NIHÀÇ NCI(±¹¸³¾Ï¿¬±¸¼Ò) »çÀÌÆ®(¾Æ·¡ 5.¿¡ ¸µÅ©)¿¡´Â °í¿ë·® ºñŸ¹ÎC¸¦ Á¤¸Æ Åõ¿©ÇÒ °æ¿ìÀÇ Ç×¾Ï È¿°ú°¡ Á¤¸®µÇ¾î ÀÖ½À´Ï´Ù. ±×°÷¿¡´Â ÀÛ¿ë ¸ÞÄ¿´ÏÁò°ú °ü·ÃÇÏ¿© ¾Æ·¡¿Í °°ÀÌ »ýü ³»¿¡¼­ H2O2(°ú»êÈ­¼ö¼Ò)¸¦ »ý¼ºÇÏ¿© Ç×¾Ï È¿°ú¸¦ ³ªÅ¸³½´Ù°í ¸»ÇÏ°í ÀÖ½À´Ï´Ù. º»·¡ Ç×»êÈ­Á¦(antioxidant)ÀÎ ºñŸ¹ÎC´Â »ýü ³»ÀÇ Á¶°Ç¿¡ µû¶ó »êÈ­ÃËÁøÁ¦(pro-oxidant)ÀÇ ¿ªÇÒÀ» ÇÏ¿© H2O2ÀÇ »ý¼º¿¡ ±â¿©ÇÒ ¼ö ÀÖÀ½Àº ÀÚ¼¼ÇÑ ¿¬±¸°¡ ¹ßÇ¥µÇ¾î ÀÖ½À´Ï´Ù. 

¡°Many laboratory studies have been done to find out how high-dose vitamin C may cause the death of cancer cells. The anticancer effect of vitamin C in different types of cancer cells involves a chemical reaction that makes hydrogen peroxide, which may kill cancer cells.¡± 

4. °í¿ë·® Á¤¸Æ Åõ¿© ºñŸ¹ÎCÀÇ ÀÓ»ó ½ÃÇè °á°ú

¹Ì NCIÀÇ °ü·Ã »çÀÌÆ® ³»¿ëÀº ¾Æ·¡ º°µµ·Î ¸µÅ©·Î ³ªÅ¸³»¾î ¼³¸íÇÏ°ÚÀ¸³ª, 2014³â ¹Ì È­ÇÐȸ(ACS)ÀÇ C&EN¿¡ ±â»ç·Î ½Ç¸° ³»¿ëÀ» ¼Ò°³ÇÕ´Ï´Ù. ACS ȸ¿øÀÌ ¾Æ´Ï¸é ¸µÅ©¸¦ ¿­ ¼ö ¾ø¾î ¸µÅ©¸¦ ´ÞÁö´Â ¾Ê½À´Ï´Ù. ĵÀÚ½º ´ëÇÐ ¸ÞµðÄà ¼¾ÅÍÀÇ Jeanne A. Drisko ÆÀÀÇ ¿¬±¸ °á°úÀÔ´Ï´Ù. ¿ì¼± ºñŸ¹Î CÀÇ Á¤¸Æ Áֻ簡 ÇÊ¿äÇÑ ÀÌÀ¯¸¦ °æ±¸ Åõ¿©¿Í ºñ±³ÇÏ¿© 1000¹è ´ÜÀ§ÀÇ Ç÷Áß ³óµµ Â÷ÀÌ·Î ¸»ÇÏ°í ÀÖ½À´Ï´Ù.   

¡°Delivered orally, Drisko says, vitamin C reaches only micromolar concentrations in the bloodstream because of poor gut absorption and quick filtering by the kidneys. Intravenous vitamin C, on the other hand, achieves therapeutically useful millimolar blood concentrations, she notes.¡°

±×·¡¼­ ¾Æ·¡¿Í °°ÀÌ 10¸íÀÇ ÁøÇàÇü ³­¼Ò¾Ï(advanced ovarian cancer) ȯÀÚ¿¡ È­Çпä¹ýÁ¦ (paclitaxel°ú carboplatin)¿Í ÇÔ²² ºñŸ¹Î C¸¦ Á¤¸ÆÀ¸·Î Åõ¿©ÇÑ °á°ú È­Çпä¹ýÁ¦ ºÎÀÛ¿ëÀÌ °¨¼ÒµÇ¾úÀ¸¸ç 5³â »ýÁ¸À²Àº ¾à°£ ³ô¾Ò´Ù(slightly higher)°í ³ªÅ¸³ª ÀÖ½À´Ï´Ù. °á·ÐÀûÀ¸·Î Drisko´Â Á» ´õ ¸¹Àº ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÏ´Â ÀÓ»ó½ÃÇèÀÇ Çʿ伺À» ¸»ÇÏ°í ÀÖ½À´Ï´Ù. 

Not ready to give up on vitamin C, (they) administered vitamin C intravenously with the chemotherapy drugs paclitaxel and carboplatin to 10 patients with advanced ovarian cancer. Members of this group experienced fewer chemotherapy side effects than patients given only paclitaxel and carboplatin. They also had a slightly higher five-year survival rate (Sci. Transl. Med. 2014, DOI: 10.1126/scitranslmed.3007154).

5. NCIÀÇ µ¿¹°½ÇÇè, ÀÓ»ó½ÃÇè ¼Ò°³

¹Ì NCIÀÇ °ü·Ã ¸µÅ©¸¦ ¾Æ·¡ ´Þ¾Ò½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº Àо½Ã±â ¹Ù¶ø´Ï´Ù. µ¿¹° ¸ðµ¨À» »ç¿ëÇÑ ½ÇÇè¿¡¼­ °í¿ë·®ÀÇ ºñŸ¹Î C°¡ ¿©·¯ ¾ÏÀÇ ¼ºÀåÀ» Â÷´ÜÇÑ´Ù´Â °Íµµ ÀÖ½À´Ï´Ù(High-dose vitamin C blocked tumor growth in animal models of pancreatic, liver, prostate, sarcoma, and ovarian cancers and malignant mesothelioma.).

ÀÓ»ó ½ÃÇèÀÇ °á°ú´Â ¾ÕÀÇ C&EN¿¡ ¼Ò°³µÈ  Drisko¿Í ºñ±³ÇÏ¿© È®ÀÎÇϽʽÿÀ(Intravenous (IV) vitamin C was studied in patients with breast cancer who were treated with adjuvant chemotherapy and radiation therapy. The study found that patients who received IV vitamin C had better quality of life and fewer side effects than those who did not.)
 
(NCI Questions and Answers About High-Dose Vitamin C)
http://www.cancer.gov/cancertopics/pdq/cam/highdosevitaminc/patient/page2

6. ¹Ì±¹ ÀÇ»çÀÇ °í¿ë·® Á¤¸Æ ºñŸ¹ÎC Åõ¿© 

¾ÕÀÇ NCI ¸µÅ©¿¡´Â ¹Ì±¹ ÀÇ»çµé °¡¿îµ¥ ¾Ï ȯÀÚ µî¿¡ °í¿ë·® ºñŸ¹Î C¸¦ Á¤¸ÆÁÖ»çÇÏ°í ÀÖÀ½ÀÌ ³ªÅ¸³ª ÀÖ½À´Ï´Ù(Surveys of healthcare practitioners at United States CAM conferences in recent years have shown that high-dose IV vitamin C is frequently given to patients as a treatment for infections, fatigue, and cancers, including breast cancer.).

±×·¯³ª ÀÌ ºñŸ¹ÎC ¿ä¹ýÀº FDAÀÇ ½ÂÀÎÀ» ¹ÞÀº ¾à°ú´Â ´Ù¸¨´Ï´Ù. °£´ÜÈ÷, Ç×¾ÏÈ¿°ú¶ó¸é ƯÁ¤ ¾Ï¿¡ ´ëÇÑ È¿°ú ÁÖÀåÀÌ Áõ¸íµÇ¾î¾ß Çϴµ¥, ÀÌ °æ¿ì´Â ´ÜÁö ¼Ò¼öÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ ÀÓ»ó ½ÃÇèÀÔ´Ï´Ù. ±×·¯³ª ¾ðÁ¨°¡ Á» ´õ ¸¹Àº ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ °á°úµµ ³ª¿Ã °ÍÀ̶ó°í ¿¹ÃøÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾ÈÀü¼º°ú °ü·ÃÇÏ¿© ¾Õ¼­ NCI ¸µÅ©¿¡´Â °í¿ë·® Á¤¸Æ Åõ¿©¿¡µµ ºñ±³Àû ¾ÈÀüÇϳª ¸ðµç ¾àÀÌ ±×·¸µíÀÌ ¿¹¿ÜÀûÀÎ °æ¿ì°¡ ¿¹½ÃµÇ¾î ÀÖ½À´Ï´Ù.   

7. ÇѺû³»°ú Åä·Ð¿¡ ´ëÇØ

¸¶Áö¸·À¸·Î 10¿© ³â Àü À§ÀÇ ÇÑ°Ü·¹21 Ä®·³°ú °ü·ÃÇÑ ÇѺû³»°ú Åä·ÐÀ̶ó´Â °ÍÀ» ¸µÅ©·Î ´ä´Ï´Ù. ±× Ä®·³À» ²¨³»µé°í ¹«¾ùÀ̶ó°í ÇÏ´Â ±èÁø¸¸°ú ÀÇ´ë±³¼ö·Î º¸ÀÌ´Â »ç¶÷ÀÇ ÅäÀÇÀε¥, Áö³­ 10¿©³â°£ ±èÁø¸¸ÀÇ ºñÁ¤»ó ÇàÀ§°¡ ±×´ë·Î µé¾î ÀÖ½À´Ï´Ù. À̶§ ±èÁø¸¸Àº »çÀ̹ö ¼¼»óÀÇ ÇϳªÀÇ ºñÁ¤»ó ¸ðµ¨À̸ç ÀÏÁ¤ ¼öÁØÀÇ Àü¹®ÀÎ ³»Áö ÀÇÇÐ Àü¹® Áö½ÄÀ» °¡Áø Àü¹®ÀǵéÀÇ ¹ÝÀÀÀ» È®ÀÎÇÒ ÇÊ¿ä°¡ ÀÖ½À´Ï´Ù.
 
´ç½Ã ±× »çÀÌÆ®¸¦ ¿î¿µÇÑ Àü³²ÀÇ´ë Ãâ½Å ÇÑ ¾Æ¹«°³ Àü¹®ÀÇ¿¡°Ô ±èÁø¸¸ÀÇ ºñ¹æ ±ÛÀ» »èÁ¦ÇØ ÁÙ °ÍÀ» ¿äûÇÏ¿´À¸³ª ±×·² ¼ö ¾ø´Ù´Â ºÎÁ¤Àû ´äº¯À» µè°í ½Ç¸ÁÀÌ ÄǽÀ´Ï´Ù. ÀÌ°ÍÀº Áö½ÄÀÇ ¹®Á¦°¡ ¾Æ´Ï¶ó Áö±ØÈ÷ Àΰ£ÀûÀÎ ¹®Á¦ÀÔ´Ï´Ù. ¿©ÇÏÆ°, ÀÌ·¯ÇÑ »çÀ̹ö ¼¼»óÀÇ ¹®Á¦, Çѹæ. ¾ç¹æ ÅäÀÇ Ã¥ ÀÛ¼º¿¡ Âü°íÇÒ ¿¹Á¤ÀÔ´Ï´Ù. 

(¹ÎÂùÈ« öÇб³¼ö °ü·Ã(11) ÇѺû³»°ú Åä·Ð, ¹Î±³¼ö°¡ ±èÁø¸¸À» À§ÇÑ´Ù¸é)
http://www.kopsa.or.kr/gnu4/bbs/board.php?bo_table=DebateCase&wr_id=124&page=5